Table 2 Pre- and postoperative clinical variables by cryoablation procedure
From: The feasibility and safety of repeat cryosurgical ablation of localized prostate cancer
Variable | First CA | Second CA | Third CA |
|---|---|---|---|
Patients (n) | 27 | 27 | 3 |
Median PSA before CA (ng/ml, range) | 5.6 (0–15) | 3 (0–6.94) | 2 (1.1–12.8) |
Median total cores at biopsy before CA (n, range) | 10 (4–14) | 12 (6–92) | 13 (12–60) |
Median positive cores at biopsy before CA (n, range) | 3 (1–12) | 2 (1–9) | 4 (1–7) |
Median percentage of positive cores before CA (%, range) | 33 (8–100) | 10 (1–75) | 8 (5–58) |
Median cumulative length of cancer at biopsy before CA (mm) | 16 (1–136) | 4.5 (1–53.5) | 17 (1–31) |
Location of cancer at apex and/or base (n %) | 15/23 (65) | 19/27 (70) | 3/3 (100) |
Location of cancer at apex (n %) | 6/23 (26) | 12/27 (44) | 1/3 (33) |
Location of cancer at base (n %) | 3/23 (13) | 4/27 (15) | 1/3 (33) |
Undetectable PSA after CA (n %) | 10/27 (37.03) | 4/27 (14.81) | 0 |
Nadir PSA after CA (ng/ml, range) | 0.65 (0.1–4.9) | 1.25 (0.2–7.9) | 1.6 (0.4–4.5) |
Duration of CA procedure (minutes) | 115 (186–169) | 100 (59–168) | 130 (109–250)a |